

# Special Issue

## Microparticles-based Vaccines

### Message from the Guest Editor

This special edition will highlight the triumphs and tribulations of microparticulate vaccine delivery. Particulate vaccines offer several advantages over the traditional vaccines, such as superior vaccine stability, the avoidance of cold-chain requirements, and the ease of manufacture. Further, the overall enhanced immune response due to a combination of factors, such as slow release of antigen from the particles and superior uptake into antigen presenting cells of the immune system, makes particulate vaccines the preferred choice of vaccine delivery. The availability of safe biodegradable and bio-compatible polymers enhances its suitability for human use. Novel delivery of microparticulate vaccines such as transdermal delivery using microneedles and laser ablation, nasal delivery, buccal delivery, and oral delivery of vaccines, amongst others, will also be discussed. Several examples of successful delivery of particulate vaccines in the areas of cancer and infectious diseases, to name a few will be extensively covered.

---

### Guest Editor

Prof. Dr. Martin J. D'Souza

Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA 30341, USA

---

### Deadline for manuscript submissions

closed (31 July 2018)



# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/si/10802](http://mdpi.com/si/10802)

*Vaccines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/](http://mdpi.com/journal/vaccines)

[vaccines](http://mdpi.com/journal/vaccines)





# Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](http://mdpi.com/journal/vaccines)

## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

